Business
Ember LifeSciences appoints Ann Hyllengren as Chief Financial Officer
Following its recent $16.5 million Series A financing in December, Ember LifeSciences, Inc., a leading provider of revolutionary cold chain technology, announced the appointment of Ann Hyllengren as Chief Financial Officer to support the company's next phase of growth.
About this update from Amgen Inc.
[{"type":"text","content":"Industry veteran to bolster executive leadership team, support company's growth","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, Jan. 21, 2026 /PRNewswire/ -- Following its recent $16.5 million Series A financing in December, Ember LifeSciences, Inc., a leading provider of revolutionary cold chain technology, announced the appointment of Ann Hyllengren as Chief Financial Officer to support the company's next phase of growth.","length":316,"tagName":"p"},{"type":"image","alt":"Ann Hyllengren, CFO","displaySize":"","headline":null,"caption":"Ann Hyllengren, CFO","className":"","disableSlideshowImg":false,"size":{"original":{"width":346,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/bcaa926174d265de18a8fcba65f10fe8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8xBXe2CP3cSHu7w64gu3kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTc0MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/bcaa926174d265de18a8fcba65f10fe8","width":346,"height":400}},"href":"https://mma.prnewswire.com/media/2863079/Ann_Hyllengren.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are thrilled to welcome Ann at a pivotal stage in our evolution," said Clay Alexander, founder and CEO of Ember LifeSciences. "She brings deep financial and operational leadership experience at one of the top life science companies in the world and will be instrumental as we develop and launch new reliable, sustainable cold chain solutions for life sciences, and beyond."","length":397,"tagName":"p"},{"type":"text","content":"Hyllengren joins Ember LifeSciences from Amgen, where she brings nearly two decades of experience across global accounting and finance, capital planning and investor relations. Most recently, she served as a senior executive on Amgen's Investor Relations team, partnering closely with executive leadership to oversee capital markets engagement and translate complex financial performance into a clear, compelling narrative for investors. She also held multiple senior finance leadership roles at Amgen, including serving as head of finance for the multibillion-dollar U.S. General Medicine business unit, where she delivered insights to inform product strategy, resource allocation and profitability. In addition, she led the management of a $1 billion annual capital...